Info for Healthcare Professionals

Noctura 400 has been designed to slow or halt the growth of weak and leaking blood vessels that can lead to diabetic retinopathy and diabetic macular oedema, by preventing the hypoxic response.
  • Safe and certified Class IIa medical device
  • Clinically proven efficacy for DR & DMO

Noctura 400 is a monitored therapy - use of the mask is detected by sensors and recorded onto a chip inside the pod.

Once the patient returns their used mask, the collected usage data can be viewed and compared to changes in vision.  

Noctura 400 is being used in clinic to treat patients with early stage DMO following the highly successful RENDER study where 96% of patients saw clinical improvement and stabilisation(2).

Across all stages of diabetic eye disease Noctura 400 has demonstrated clinical repair in 66% of patients, and no associated complications(2-6).

NICE have published a Medtech Innovation Briefing for Noctura 400 (6)

Noctura 400 has been used for people with
– Mild to moderate non-proliferative diabetic retinopathy (1,2)
– Early, untreated and progressive diabetic macular oedema (2-5)
– Moderate proliferative diabetic retinopathy (2)

After a period of treatment patients experience:

Retinal Thickness 2,3,5

Retinal Cysts 3,4,5

Visual Acuity 2,5

Patient Data and Results

Patient A

Before Noctura 400
After 3 months
After 12 Months
3 months mask usage

Patient B

Before Noctura 400
After 3 months
After 12 Months
3 months mask usage

Patient C

Before Noctura 400
After 3 months
After 12 Months
After 12 Months


If you would like more information on how to provide Noctura 400 for your patients, contact us.

How to provide Noctura 400 for your patients

Phone 01740 625 555 (Mon-Fri 9am-5pm)

© 2023 All rights reserved | Website by Myk Baxter Marketing

Contact Us

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.